Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | BPTF | Q12830 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.34 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13493179 | 0.89 | MDM2 (0.37) | LMNAHTTCYP1A2GRM4CHRM4 | |
| SCHEMBL731967 | 0.87 | KMT2A (0.51) | LMNAHTTCHRNB2CHRNA4KMT2A | |
| SCHEMBL12536963 | 0.86 | TACR3 (0.38) | PANK3CHRM4 | |
| SCHEMBL2304054 | 0.83 | HTT (0.51) | LMNAHTTCHRNB2CHRNA4KMT2A | |
| SCHEMBL4229828 | 0.81 | HRH3 (0.34) | CYP1A2GRM4 | |
| SCHEMBL733502 | 0.80 | HRH3 (0.35) | HTTSMN1; SMN2CYP1A2GRM4 | |
| SCHEMBL3262449 | 0.80 | HRH3 (0.35) | HTTSMN1; SMN2CYP1A2GRM4 | |
| SCHEMBL12536953 | 0.80 | ALDH1A1 (0.42) | LMNAKMT2AMEN1SMN1; SMN2GRM4 | |
| SCHEMBL731792 | 0.77 | MC4R (0.54) | — | |
| SCHEMBL731793 | 0.77 | MC4R (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989196-B1 | PIPERIDINOYLPYRROLIDINES AS MELANOCORTIN TYPE 4 RECEPTOR AGONISTS | PFIZER LTD (GB) | 2013-02-13 | — | — | EP | disclosed |
| US-20090036459-A1 | Melanocortin Type 4 Receptor Agonist Piperidinoylpyrrolidines | PFIZER INC | 2009-02-05 | — | — | US | disclosed |
| EP-1989196-A2 | MELANOCORTIN TYPE 4 RECEPTOR AGONIST PIPERIDINOYLPYRROLIDINES | Pfizer Limited (GB) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007096763-A2 | MELANOCORTIN TYPE 4 RECEPTOR AGONIST PIPERIDINOYLPYRROLIDINES | PFIZER LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036459-A1 | Melanocortin Type 4 Receptor Agonist Piperidinoylpyrrolidines | MC4R, MC5R, MC3R | LMNA 4738/4885HTT 2777/4885CHRNB2 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.